Results

1–10 of 15 results for anti VEGF injection

Survey of Intravitreal Injection Technique Among Retina Specialists in Mexico
Gabriela Lopezcarasa Hernandez, MD
On Demand Cases, Courses, and Papers
2021
PRN Cycles of Three Monthly Anti-VEGF Injections in Diabetic Macular Edema: 12- and 24-Month Results
Ahmad Rehmani, DO
On Demand Cases, Courses, and Papers
2021
The Influence of Universal Face Mask Use on Endophthalmitis Risk After Intravitreal Anti-VEGF Injections During the COVID-19 Pandemic
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Longitudinal Total Retinal Fluid Index Assessment in nAMD From the OSPREY Study: A Novel Assessment of Fluid Drying Effect
Sunil Srivastava, MD
On Demand Cases, Courses, and Papers
2020
Characteristics of Fellow Eye Conversion to Neovascular Age-Related Macular Degeneration in Patients With Unilateral Neovascular Disease
Matthew Starr, MD
Annual Meeting Talks
2020
Two-Year Real-World Treat and Extend Patterns and Fluid Outcomes Among Neovascular Age-Related Macular Degeneration Patients Treated With Anti-VEGFs
Michael A. Singer, MD
Annual Meeting Talks
2020
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020
Modifier-25 Examinations Reduce Travel Burden, Decrease Treatment Cost, and Improve QALY for Exudative Age-Related Macular Degeneration Patients
Henry A Leder, MD
Annual Meeting Talks
2020
Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD
Rahul Komati, MD
Annual Meeting Talks
2020